- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
FDA expands ipilimumab approval to pediatric melanoma
The US Food and Drug Administration (FDA) has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease.
The US Food and Drug Administration (FDA) has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease, CancerNetwork reports. The FDA-approved ipilimumab dose for pediatric melanoma patients is 3 mg/kg, administered intravenously every 3 weeks for four doses.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
The Future of laBCC Treatment with Vishal Patel, MD, FAAD, FACMS
Apoptosis-Based Skin Cancer Treatment Shows Promise
Mastering Dermoscopy and Dysplastic Nevi
The Future of AI in Dermatology with Andy Beck, MD, PhD
How PathAI’s PathAssist Derm Tool Aims to Enhance Skin Cancer Diagnosis and Workflow Efficiency
Expanding Collaborations in the Fight Against Skin Cancer
Spearheading Awareness Campaigns for Skin Cancer Prevention and Sun Protection
Resources for Patients and Clinicians from the Skin Cancer Foundation
2025 Goals and Priorities of The Skin Cancer Foundation: An Interview with Executive Director, Becky Kamowitz
BCC Patient Case Impressions
Related Content
